FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010562010> ?p ?o ?g. }

• W3010562010 endingPage "e001145" @default.
• W3010562010 startingPage "e001145" @default.
• W3010562010 abstract "Objectives To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). Methods Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (≥2.1) and BASDAI (≥4) definitions of high disease activity) were compared regarding baseline characteristics and response to bDMARDs at 3 and 6 months estimated in multivariable regression models. Results Of the 594 patients included, the majority (82%) had both BASDAI≥4 and ASDAS ≥2.1. The frequency of ASDAS ≥2.1, if BASDAI<4 was much larger than the opposite (ie, ASDAS <2.1, if BASDAI≥4): 62% vs 0.8%. Compared to patients fulfilling both definitions, those with ASDAS ≥2.1 only were more likely to be male (77% vs 51%), human leucocyte antigen B27 positive (79% vs 65%) and have a higher C reactive protein (2.9 (SD 3.5) vs 2.1 (2.9)). Among bDMARD-treated patients (n=359), responses across subgroups were globally overlapping, except for the most ‘stringent’ outcomes. Patients captured only by ASDAS responded better compared to patients fulfilling both definitions (eg, ASDAS inactive disease at 3 months: 61% vs 25% and at 6 months: 42% vs 25%). Conclusion The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally ‘captured’ patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS≥2.1 as a criterion for treatment decisions." @default.
• W3010562010 created "2020-03-13" @default.
• W3010562010 creator A5002709346 @default.
• W3010562010 creator A5002875386 @default.
• W3010562010 creator A5003059891 @default.
• W3010562010 creator A5012327980 @default.
• W3010562010 creator A5022032113 @default.
• W3010562010 creator A5024841743 @default.
• W3010562010 creator A5029273559 @default.
• W3010562010 creator A5043668531 @default.
• W3010562010 creator A5044724637 @default.
• W3010562010 creator A5047759387 @default.
• W3010562010 creator A5048122879 @default.
• W3010562010 creator A5052060110 @default.
• W3010562010 creator A5057223678 @default.
• W3010562010 creator A5063022541 @default.
• W3010562010 creator A5066446952 @default.
• W3010562010 creator A5068073716 @default.
• W3010562010 creator A5075879751 @default.
• W3010562010 creator A5085359664 @default.
• W3010562010 creator A5088107398 @default.
• W3010562010 creator A5091126812 @default.
• W3010562010 date "2020-01-01" @default.
• W3010562010 modified "2023-10-01" @default.
• W3010562010 title "Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI" @default.
• W3010562010 cites W1966756689 @default.
• W3010562010 cites W1980550182 @default.
• W3010562010 cites W1983371526 @default.
• W3010562010 cites W2006973385 @default.
• W3010562010 cites W2015406536 @default.
• W3010562010 cites W2050233086 @default.
• W3010562010 cites W2076685991 @default.
• W3010562010 cites W2077615804 @default.
• W3010562010 cites W2089579409 @default.
• W3010562010 cites W2095816100 @default.
• W3010562010 cites W2101828772 @default.
• W3010562010 cites W2103874459 @default.
• W3010562010 cites W2128432930 @default.
• W3010562010 cites W2129501695 @default.
• W3010562010 cites W2133242189 @default.
• W3010562010 cites W2137068168 @default.
• W3010562010 cites W2139351039 @default.
• W3010562010 cites W2141081169 @default.
• W3010562010 cites W2156371898 @default.
• W3010562010 cites W2156605473 @default.
• W3010562010 cites W2162319272 @default.
• W3010562010 cites W2163741803 @default.
• W3010562010 cites W2788828749 @default.
• W3010562010 doi "https://doi.org/10.1136/rmdopen-2019-001145" @default.
• W3010562010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7061099" @default.
• W3010562010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32144137" @default.
• W3010562010 hasPublicationYear "2020" @default.
• W3010562010 type Work @default.
• W3010562010 sameAs 3010562010 @default.
• W3010562010 citedByCount "11" @default.
• W3010562010 countsByYear W30105620102020 @default.
• W3010562010 countsByYear W30105620102021 @default.
• W3010562010 countsByYear W30105620102022 @default.
• W3010562010 countsByYear W30105620102023 @default.
• W3010562010 crossrefType "journal-article" @default.
• W3010562010 hasAuthorship W3010562010A5002709346 @default.
• W3010562010 hasAuthorship W3010562010A5002875386 @default.
• W3010562010 hasAuthorship W3010562010A5003059891 @default.
• W3010562010 hasAuthorship W3010562010A5012327980 @default.
• W3010562010 hasAuthorship W3010562010A5022032113 @default.
• W3010562010 hasAuthorship W3010562010A5024841743 @default.
• W3010562010 hasAuthorship W3010562010A5029273559 @default.
• W3010562010 hasAuthorship W3010562010A5043668531 @default.
• W3010562010 hasAuthorship W3010562010A5044724637 @default.
• W3010562010 hasAuthorship W3010562010A5047759387 @default.
• W3010562010 hasAuthorship W3010562010A5048122879 @default.
• W3010562010 hasAuthorship W3010562010A5052060110 @default.
• W3010562010 hasAuthorship W3010562010A5057223678 @default.
• W3010562010 hasAuthorship W3010562010A5063022541 @default.
• W3010562010 hasAuthorship W3010562010A5066446952 @default.
• W3010562010 hasAuthorship W3010562010A5068073716 @default.
• W3010562010 hasAuthorship W3010562010A5075879751 @default.
• W3010562010 hasAuthorship W3010562010A5085359664 @default.
• W3010562010 hasAuthorship W3010562010A5088107398 @default.
• W3010562010 hasAuthorship W3010562010A5091126812 @default.
• W3010562010 hasBestOaLocation W30105620101 @default.
• W3010562010 hasConcept C126322002 @default.
• W3010562010 hasConcept C1862650 @default.
• W3010562010 hasConcept C2776213234 @default.
• W3010562010 hasConcept C2776260265 @default.
• W3010562010 hasConcept C2777402515 @default.
• W3010562010 hasConcept C2777453003 @default.
• W3010562010 hasConcept C2778579456 @default.
• W3010562010 hasConcept C2779134260 @default.
• W3010562010 hasConcept C2908564923 @default.
• W3010562010 hasConcept C2909063479 @default.
• W3010562010 hasConcept C71924100 @default.
• W3010562010 hasConceptScore W3010562010C126322002 @default.
• W3010562010 hasConceptScore W3010562010C1862650 @default.
• W3010562010 hasConceptScore W3010562010C2776213234 @default.
• W3010562010 hasConceptScore W3010562010C2776260265 @default.
• W3010562010 hasConceptScore W3010562010C2777402515 @default.
• W3010562010 hasConceptScore W3010562010C2777453003 @default.

• next